| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 05/16/2001 | CN1295482A Antagonists of the inflammatory mediator oncostatin M (OSM) |
| 05/16/2001 | CN1295481A 疫苗组合物 Vaccine composition |
| 05/16/2001 | CN1295480A Vaccines comprising interleukin-12 and respiratory syncytial viral antigens |
| 05/16/2001 | CN1295081A Human tumor related nucleoprotein 24 and its code sequence |
| 05/16/2001 | CN1065912C Genetically engineered attenuated viruses |
| 05/15/2001 | US6232522 Non-human animal model for systemic lupus erythematosis |
| 05/15/2001 | US6232460 Isolated nucleic acid molecule which encodes an SCP-1 mutein |
| 05/15/2001 | US6232454 Nucleic acid and amino acid sequences and use in diagnosis, treatment, and prevention of cancer and immune disorders |
| 05/15/2001 | US6232452 Autosomal dominant disorder of growths in many tissues and organs identified on chromosome 16 deletion mutations; use in disease diagnosis and screening; the gene may behave as a tumor suppressor |
| 05/15/2001 | US6232443 Useful markers in diagnosing and monitoring cancerous renal cells; detecting cell proliferative disorders |
| 05/15/2001 | US6232441 PIGR-1, a member of immunoglobulin gene superfamily |
| 05/15/2001 | US6232292 3-dehydroquinate synthase |
| 05/15/2001 | US6232289 Method of treating interstitial cytitis with recombinant heparin-binding epidermal growth factor-like growth factor (HB-EGF) |
| 05/15/2001 | US6232286 Methods of stimulating mitogenesis in glial cells using glial mitogenic factors |
| 05/15/2001 | US6232116 Oral administration of pneumococcal antigens |
| 05/15/2001 | US6232097 Nucleotide sequences coding enzymatic polypeptide; prevent bacterial infection; wound healing agents; for vaccine development |
| 05/15/2001 | US6232096 Flea serine protease nucleic acid molecules and uses thereof |
| 05/15/2001 | US6232082 Vaccines |
| 05/15/2001 | US6232077 Genetic engineering and expression; cancer diagnosis |
| 05/15/2001 | US6232064 Fibrosis and atherosclerosis determination |
| 05/15/2001 | US6231882 Mixed micellar delivery system and method of preparation |
| 05/15/2001 | US6231871 Live in ovo vaccine |
| 05/15/2001 | US6231870 Oral administration of pneumoccal antigens |
| 05/15/2001 | US6231864 Strategically modified hepatitis B core proteins and their derivatives |
| 05/15/2001 | US6231863 DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same |
| 05/15/2001 | US6231861 Plasmodium vivax blood stage antigens, antibodies, and diagnostic assays |
| 05/15/2001 | US6231860 Stabilizers for live vaccines |
| 05/15/2001 | US6231859 Saponin adjuvant compositions |
| 05/15/2001 | US6231855 Side effect reduction |
| 05/15/2001 | US6231536 Method and compositions for treatments of cancers |
| 05/15/2001 | CA2183268C Bispecific molecules having clinical utilities |
| 05/15/2001 | CA2078858C Expression of heterologous protein in yeast |
| 05/15/2001 | CA2041638C Recombinant polynucleotide constructs suitable for providing secretion of pai-2 |
| 05/15/2001 | CA1341234C Recombinant fowlpox virus |
| 05/12/2001 | CA2325619A1 A method for preventing and inhibiting human hla alloimmune response to platelet transfusion |
| 05/10/2001 | WO2001033221A1 Axor35, a g-protein coupled receptor |
| 05/10/2001 | WO2001033218A1 Method for identifying active anti-apoptosis compounds |
| 05/10/2001 | WO2001032926A2 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | WO2001032925A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | WO2001032893A1 Recombinant therapeutic fusion proteins |
| 05/10/2001 | WO2001032882A2 Nucleic acids and proteins from group b streptococcus |
| 05/10/2001 | WO2001032878A2 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | WO2001032877A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 05/10/2001 | WO2001032864A2 Gpcr-kd5 polypeptides and dna sequences thereof |
| 05/10/2001 | WO2001032843A2 Enhanced immune recognition of pathogenic cells by icsbp expression |
| 05/10/2001 | WO2001032714A1 Recombinant fusion molecules |
| 05/10/2001 | WO2001032713A1 Production of mammary secretion antibodies in farm animals |
| 05/10/2001 | WO2001032702A2 Molecular structure of rhd negative locus |
| 05/10/2001 | WO2001032697A2 Virulence genes and proteins from brucella melitensis, and their use |
| 05/10/2001 | WO2001032696A2 Traf family proteins |
| 05/10/2001 | WO2001032695A2 MODULATION OF eNOS ACTIVITY AND THERAPEUTIC USES THEREOF |
| 05/10/2001 | WO2001032692A2 Peptide mimics of conserved gonococcal epitopes and methods and compositions using them |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032676A1 25 human secreted proteins |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032674A1 26 human secreted proteins |
| 05/10/2001 | WO2001032614A2 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | WO2001032221A1 Dna-vaccines based on constructs derived from the genomes of human and animal pathogens |
| 05/10/2001 | WO2001032209A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/10/2001 | WO2001032208A1 Adjuvanted genetic vaccines |
| 05/10/2001 | WO2001032207A1 Methods for conferring active/passive immunotherapy |
| 05/10/2001 | WO2001032205A1 Mucosal preventives for mastitis |
| 05/10/2001 | WO2001032204A2 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | WO2001032193A1 Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma |
| 05/10/2001 | WO2001032189A1 Supernatant from mesenchymal stem cells for prevention and treatment of immune responses in transplantation |
| 05/10/2001 | WO2001032154A2 Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032070A2 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 05/10/2001 | WO2001032009A1 Propagation of human hepatocytes in non-human animals |
| 05/10/2001 | WO2001021806B1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/10/2001 | WO2001021804B1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/10/2001 | WO2001021803B1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 05/10/2001 | WO2001010459A3 Fish vaccine |
| 05/10/2001 | WO2001007480A3 Use of interleukin-18 inhibitors to inhibit tumor metastasis |
| 05/10/2001 | WO2000077207A3 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto |
| 05/10/2001 | WO2000075191A3 Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM |
| 05/10/2001 | WO2000064488A3 Somatic transgene immunization and related methods |
| 05/10/2001 | WO2000061635A3 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-egp-2 scfv fragment |
| 05/10/2001 | WO2000061067B1 Anti-hiv 1 vaccine comprising the entire or part of the tat hiv-1 protein |
| 05/10/2001 | WO2000034334A9 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 05/10/2001 | WO1999052503A3 Rna cancer vaccine and methods for its use |
| 05/10/2001 | US20010001098 Precore sequences in the 5' untranslated region of the core antigen mRNA are not present |
| 05/10/2001 | US20010001040 Alteration of macrophage-induced T cell suppression or concentration by the selective elimination or increase of tryptophan by administering an enzyme inhibitor of indole-amino 2,3-deoxygenase; viricides; abortion; fertility; |
| 05/10/2001 | DE19952960A1 Verfahren zur Identifizierung von anti-apoptotisch wirksamen Verbindungen A method of identifying anti-apoptotically active compounds |
| 05/10/2001 | CA2389964A1 A novel method of diagnosing, monitoring, staging, imaging and treating cancer |
| 05/10/2001 | CA2389849A1 Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
| 05/10/2001 | CA2389765A1 Cpg receptor (cpg-r) and methods relating thereto |
| 05/10/2001 | CA2389751A1 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | CA2389693A1 Dna-vaccines based on constructs derived from the genomes of human and animal pathogens |
| 05/10/2001 | CA2389686A1 Adjuvanted genetic vaccines |
| 05/10/2001 | CA2389680A1 Nucleic acid vaccine compositions having a mammalian cd80/cd86 gene promoter driving antigen expression |
| 05/10/2001 | CA2389646A1 Propagation of human hepatocytes in non-human animals |
| 05/10/2001 | CA2389644A1 A novel polypeptide hormone phosphatonin |
| 05/10/2001 | CA2389575A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389339A1 Recombinant therapeutic fusion proteins |
| 05/10/2001 | CA2388955A1 Recombinant fusion molecules |
| 05/10/2001 | CA2388308A1 Gpcr-kd5 polypeptides and dna sequences thereof |
| 05/10/2001 | CA2387754A1 10 human secreted proteins |
| 05/10/2001 | CA2387261A1 25 human secreted proteins |